Loading
Latest filing published 08 Dec 2025 for Quince Therapeutics, Inc., €1,073. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Brendan Hannah is a declared insider of IRulya Therapeutics Inc. (senior executive), with filings sourced from SEC (Form 4). The record holds 7 filings, for trades running from 19 May 2022 to 5 December 2025.
On the market, this insider has only ever bought: 2 purchases, €81k in total. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Other entries cover 3 share grants and 2 option exercises.
Most recently, on 8 December 2025, the filings show an option exercise worth €1,073 in IRulya Therapeutics Inc. The latest purchase dates back some time: it was published 788 days ago, on 21 August 2024. Typically, a trade is published a median of 3 days after it takes place. Section 16 rules allow two business days to file each Form 4. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
7 of 7 declarations